Trial Profile

An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amatuximab (Primary) ; Cisplatin; Pemetrexed
Indications Malignant-mesothelioma
Focus Therapeutic Use
Sponsors Morphotek

Most Recent Events

12 Apr 2019 According to Eudra database the trial has been completed in Spain.
23 May 2014 According to ClinicalTrials.gov reocrd, status changed from active, no longer recruiting to completed.
23 May 2014 According to ClinicalTrials.gov reocrd, status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com